{"id":"docetaxel-and-reolysin","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Neutropenia"},{"rate":"20-40%","effect":"Fatigue"},{"rate":"20-40%","effect":"Nausea"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"10-30%","effect":"Anemia"}]},"_chembl":{"chemblId":"CHEMBL92","moleculeType":"Small molecule","molecularWeight":"807.89"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Docetaxel works by binding to tubulin and preventing the formation of microtubules, which are essential for cell division. This leads to cell cycle arrest and apoptosis in rapidly dividing cancer cells. Reolysin, on the other hand, is a recombinant reovirus that selectively infects and kills cancer cells by inducing apoptosis and inhibiting angiogenesis.","oneSentence":"Docetaxel is a microtubule inhibitor that disrupts cell division, while Reolysin is a viral therapy that selectively infects and kills cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:11:01.472Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Locally advanced or metastatic breast cancer, Non-small cell lung cancer, Pancreatic cancer"}]},"trialDetails":[{"nctId":"NCT01619813","phase":"PHASE2","title":"Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Canadian Cancer Trials Group","startDate":"2012-12-14","conditions":"Prostate Cancer","enrollment":85},{"nctId":"NCT01708993","phase":"PHASE2","title":"Reolysin in Previously Treated Advanced/Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy","status":"COMPLETED","sponsor":"Canadian Cancer Trials Group","startDate":"2012-12-10","conditions":"Non Small Cell Lung Cancer","enrollment":166}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Docetaxel and Reolysin","genericName":"Docetaxel and Reolysin","companyName":"Canadian Cancer Trials Group","companyId":"canadian-cancer-trials-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Docetaxel is a microtubule inhibitor that disrupts cell division, while Reolysin is a viral therapy that selectively infects and kills cancer cells. Used for Locally advanced or metastatic breast cancer, Non-small cell lung cancer, Pancreatic cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}